NTRA · Natera Inc
Price
Snapshot
50 fields · last close| Market Cap | $56.71B |
| P/E | — |
| Float | 138.8M |
| Beta | 1.54 |
| Volatility | 38.6% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 68.2 |
| Price | 403.14 |
| Change | +2.47% |
| Prev Close | 393.44 |
| Open | 405.76 |
| Day Low | 387.26 |
| Day High | 410.63 |
| Avg Vol | 2 |
| Avg $ Vol | $656.9M |
| 52W High | 437.41 |
| 52W Low | 178.01 |
| 52W Pos | 86.8% |
| From High | −7.83% |
| From Low | +126.47% |
| Max DD 1Y | −28.20% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +0.39% |
| SMA 50 | +12.58% |
| SMA 200 | +56.56% |
| RSI (14) | 54.9 |
| Vol 30D | 39.8% |
| Vol 90D | 50.2% |
| 1Y Range | 178–437 |
| Daily bars | 536 |
| Perf Week | −1.81% |
| Perf Month | +7.41% |
| Perf Quarter | +49.81% |
| Perf Half Y | +88.79% |
| Perf Year | +119.28% |
| Perf YTD | +76.17% |
| Prev Day | +2.47% |
| Clavix | B- |
| Debt / Eq | 0.17 |
| Curr Ratio | 3.39 |
| Int Cover | -39.2× |
| FCF Margin | 4.7% |
| Rev Growth | +35.9% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 22 / 35 |
Clavix risk grade
regraded every trading dayNTRA grades B-, 68.2 of 100. Steadiest on Sector Resilience (67), most exposed on Price Stability (50, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 22 of 35 in Biotechnology by Clavix score.
How rough the ride is
| NTRA | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.54 | 0.51 |
| Volatilityannualized | 38.6% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −28.2% | — |
| Typical daily movemedian absolute daily change | 1.54% | — |
| Days beyond ±3%of the last 252 sessions | 63 (25%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| NTRA | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.54 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| NTRA | |
|---|---|
| 1 week | −1.8% |
| 1 month | +7.4% |
| Year to date | +76.2% |
| 1 year | +119.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| NTRA | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 28 Aug |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 3 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| NTRA | |
|---|---|
| Revenue growthyear over year | +35.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAssenagon Asset Management S.A. reduced its holdings in Natera (NTRA) by 37.4% in the third quarter, selling 93,873 shares and leaving it with 156,996 shares. The article is incomplete and cuts off mid-sentence.
Natera announced that its Signatera molecular residual disease (MRD) test was named to TIME's Best Inventions of 2026 list. The article is truncated and does not include further details about the selection criteria or any financial impact.
JPMorgan raised their price target on Natera from $360 to $460, a roughly 28% increase, and assigned the stock an 'overweight' rating. No other company-specific information was reported.
Natera announced a collaboration with TransCode Therapeutics to support enrollment in TransCode's Phase 2a trial of TTX-MC138, a drug candidate for colorectal cancer.
Natera announced a collaboration with TransCode Therapeutics to support a Phase 2a clinical trial of TransCode's drug TTX-MC138 in colorectal cancer, bringing Natera's cell-free DNA and precision medicine platform into the study.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | B+ | $81.41B | 18.81 | 0.13 | Compare |
| RVMD | Revolution Medicines Inc | B- | $38.14B | — | 1.44 | Compare |
| MRNA | Moderna Inc | F | $87.04B | — | 1.17 | Compare |
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $31.02B | 38.39 | 0.37 | Compare |
| VRTX | Vertex Pharmaceuticals Inc | B+ | $126.7B | 28.75 | 0.29 | Compare |
| INCY | Incyte Corp | B+ | $22.92B | 14.21 | 0.79 | Compare |
| UTHR | United Therapeutics Corp | B | $22.87B | 17.44 | 0.50 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.